~~<i id='696D700A21'><strike id='696D700A21'><tt id='696D700A21'><pre id='696D700A21'></pre></tt></strike></i>~~

Home» knowledge» leisure time

leisure time

author：explore 2025-09-27 10:30:48 Page View：3943

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Patients, digital health players weigh in on FTC's data privacy plan
Next article： Moonlake's readout produced a cash windfall. Risks remain

comprehensive

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

ALS treatment from Biogen, Ionis fails in study

RubyWallauforSTATAplantousenewgenetictechniquestotreatnon-geneticformsofALSfailedinanearlystudy,Ioni

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Senators push IRS to launch nonprofit hospital probe

Abipartisangroupofsenatorswantsfederaltaxregulatorstoprobenonprofithospitals’compliancewithcommunity